Floatz logo

vx-970

Stage IV Lung Cancer AJCC v8

National Cancer Institute (NCI)Phase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
81/ 100

Competitive context

303 Active assets in the Stage IV Lung Cancer AJCC v8 cohort.

View all 50

Same molecule, other indications

vx-970 is also rated in:

small cell lung carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
small cell carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
fallopian tube carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →